Notícias

MRNA keeps its 2026 growth target intact while cutting cost guidance and advancing flu, oncology and rare-disease programs toward key milestones.

The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment.

The company topped Wall Street loss estimates, but its norovirus vaccine missed a key trial goal, sending shares lower

In the most recent trading session, Moderna (MRNA) closed at $59.49, indicating a -3.77% shift from the previous trading day.

Moderna (MRNA) reached $66.98 at the closing of the latest trading day, reflecting a -1.89% change compared to its last close.

The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns.

Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally hit a wall.

(Updates with latest market prices and developments.) US stocks were lower intraday after Preside

US stocks are expected to extend losses on Wednesday after oil prices spiked following an exchange of strikes between the US and Iran that led to President Donald Trump declaring the ceasefire "over". Dow Jones futures were down 1.1%, with S&P 500 futures pointing to a 0.9% drop, while...

When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.

US equity indexes were lower on Friday amid a sell-off in technology stocks and despite a decline in

Stock Market Today: The Dow Jones index rose Thursday ahead of jobless claims data. Intel stock surged on Trump's comments.

Retail investors reassess growth favorites as Robinhood’s job cuts ripple through a market tilting toward industrial and financial stocks, today, June 16, 2026.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.

In May 2026, Roivant Sciences reported fourth-quarter 2026 results showing sales of US$2.52 million, a swing to quarterly net income of US$302.99 million, and full-year 2026 sales of US$8.26 million alongside a wider annual net loss of US$299.77 million. The earnings were heavily influenced by a US$770.2 million litigation settlement gain linked to Genevant’s US$2.25 billion global patent settlement with Moderna, highlighting how non-operating items and asset monetization can meaningfully...

On May 6, 2026, Moderna’s board amended its bylaws to require Securities Act of 1933 lawsuits be filed exclusively in US federal district courts, aligning with recent Delaware law changes, while the FDA set a June 18 advisory panel review for the company’s mRNA-based seasonal flu vaccine after an earlier filing setback. Together with ongoing insider share sales under a preset trading plan and fresh real-world data on its pediatric COVID-19 vaccine effectiveness, these developments sharpen...

The U.S. health department said one passenger on a repatriation flight has tested mildly positive for the virus, while another is currently experiencing mild symptoms.